Skip to main content
Have a personal or library account? Click to login
What’s New with TAVR? An Update on Device Technology Cover

What’s New with TAVR? An Update on Device Technology

Open Access
|May 2023

References

  1. Cribier A, Eltchaninoff H, Tron C, et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol. 2004 Feb 18;43(4):698-703. doi: 10.1016/j.jacc.2003.11.026
  2. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002 Dec 10;106(24):3006-8. doi: 10.1161/01.cir.0000047200.36165.b8
  3. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-e71. doi: 10.1161/CIR.0000000000000932
  4. Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2020 Nov 24;76(21):2492-2516. doi: 10.1016/j.jacc.2020.09.595
  5. Cahill TJ, Chen M, Hayashida K, et al. Transcatheter aortic valve implantation: current status and future perspectives. Eur Heart J. 2018 Jul 21;39(28):2625-2634. doi: 10.1093/eurheartj/ehy244
  6. Tchetche D, Van Mieghem NM. New-generation TAVI devices: description and specifications. EuroIntervention. 2014 Sep;10 Suppl U:U90-U100. doi: 10.4244/EIJV10SUA13
  7. van Gils L, Tchetche D, Latib A, et al. TAVI with current CE-marked devices: strategies for optimal sizing and valve delivery. EuroIntervention. 2016 Sep 18;12(Y):Y22-7. doi: 10.4244/EIJV12SYA6
  8. Chamandi C, Puri R, Rodriguez-Gabella T, Rodés-Cabau J. Latest-Generation Transcatheter Aortic Valve Replacement Devices and Procedures. Can J Cardiol. 2017 Sep;33(9):1082-1090. doi: 10.1016/j.cjca.2017.03.012
  9. Cannata S, Gandolfo C, Ribichini FL, et al. One-year outcomes after transcatheter aortic valve implantation with the latest-generation SAPIEN balloon-expandable valve: the S3U registry. EuroIntervention. 2023 Mar 7;EIJ-D-22-01022. doi: 10.4244/EIJ-D-22-01022
  10. Nazif TM, Cahill TJ, Daniels D, et al. Real-World Experience With the SAPIEN 3 Ultra Transcatheter Heart Valve: A Propensity-Matched Analysis From the United States. Circ Cardiovasc Interv. 2021 Sep;14(9):e010543. doi: 10.1161/CIRCINTERVENTIONS.121.010543
  11. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2023. ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve; 2022 Dec 12 [cited 2023 Apr 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT05172960
  12. Tang GHL, Zaid S, Michev I, et al. “Cusp-Overlap” View Simplifies Fluoroscopy-Guided Implantation of Self-Expanding Valve in Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2018 Aug 27;11(16):1663-1665. doi: 10.1016/j.jcin.2018.03.018
  13. Zaid S, Sengupta A, Okoli K, et al. Novel Anatomic Predictors of New Persistent Left Bundle Branch Block After Evolut Transcatheter Aortic Valve Implantation. Am J Cardiol. 2020 Apr 15;125(8):1222-1229. doi: 10.1016/j.amjcard.2020.01.008
  14. Yoon SH, Galo J, Amoah JK, et al. Permanent Pacemaker Insertion Reduction and Optimized Temporary Pacemaker Management After Contemporary Transcatheter Aortic Valve Implantation With Self-Expanding Valves (from the Pristine TAVI Study). Am J Cardiol. 2023 Feb 15;189:1-10. doi: 10.1016/j.amjcard.2022.11.026
  15. Doldi PM, Stolz L, Escher F, et al. Transcatheter Aortic Valve Replacement with the Self-Expandable Core Valve Evolut Prosthesis Using the Cusp-Overlap vs. Tricusp-View. J Clin Med. 2022 Mar 12;11(6):1561. doi: 10.3390/jcm11061561
  16. Gada H, Vora AN, Tang GHL, et al. Site-Level Variation and Predictors of Permanent Pacemaker Implantation Following TAVR in the Evolut Low-Risk Trial. Cardiovasc Revasc Med. 2023 Feb;47:48-54. doi: 10.1016/j.carrev.2022.10.004
  17. Khera S, Krishnamoorthy P, Sharma SK, et al. Improved Commissural Alignment in TAVR With the Newest Evolut FX Self-Expanding Supra-Annular Valve: First-in-Human Experience. JACC Cardiovasc Interv. 2023 Feb 27;16(4):498-500. doi: 10.1016/j.jcin.2022.10.041
  18. Tang GHL, Krishnamoorthy P, Khera S, et al. First-in-Human Multicentre Experience of TAVI with the Supra-annular, Self-Expanding Evolut FX System. PCR London Valves Annual Meeting; London, UK; 2022. Paris: France; PCR Online; 2022.
  19. Sondergaard L, Walton AS, Worthley SG, et al. Thirty-day and one-year outcomes of the Navitor transcatheter heart valve in patients with aortic stenosis: the prospective, multicentre, global PORTICO NG Study. EuroIntervention. 2023 Mar 9;EIJ-D-22-01108. doi: 10.4244/EIJ-D-22-01108
  20. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2023. Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation (VANTAGE); 2023 Jan 9 [cited 2023 Apr 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04788888
  21. Lanz J, Kim WK, Walther T, et al. Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. Lancet. 2019 Nov 2;394(10209):1619-1628. doi: 10.1016/S0140-6736(19)32220-2
  22. Tamburino C, Bleiziffer S, Thiele H, et al. Comparison of Self-Expanding Bioprostheses for Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis: SCOPE 2 Randomized Clinical Trial. Circulation. 2020 Dec 22;142(25):2431-2442. doi: 10.1161/CIRCULATIONAHA.120.051547
  23. Buono A, Gorla R, Ielasi A, et al. Transcatheter Aortic Valve Replacement With Self-Expanding ACURATE neo2: Postprocedural Hemodynamic and Short-Term Clinical Outcomes. JACC Cardiovasc Interv. 2022 Jun 13;15(11):1101-1110. doi: 10.1016/j.jcin.2022.02.027
  24. Ruck A. Results from the Early neo2 Registry Acurate neo2 TAVI Valve. Congress for the European Association of Percutaneous Cardiovascular Interventions (EuroPCR); 2021 May 18-20; Paris, France. Available from: https://media.pcronline.com/diapos/EuroPCR2021/3890-20210518_0922_Clinical_Science_Ruck_Andreas_0000_(7805)/Ruck_Andreas_20211805_1408_VOD.pdf
  25. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2023. ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement; 2023 Mar 30 [cited 2023 Apr 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03735667
  26. Yoon SH, Schmidt T, Bleiziffer S, et al. Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation. J Am Coll Cardiol. 2017 Dec 5;70(22):2752-2763. doi: 10.1016/j.jacc.2017.10.006
  27. Kempfert J, Rastan AJ, Mohr FW, Walther T. A new self-expanding transcatheter aortic valve for transapical implantation - first in man implantation of the JenaValve™. Eur J Cardiothorac Surg. 2011 Sep;40(3):761-3. doi: 10.1016/j.ejcts.2010.12.063
  28. Nijenhuis VJ, Swaans MJ, Michiels V, de Kroon T, Heijmen RH, Ten Berg JM. “First experience with JenaValve™: a single-centre cohort”. Neth Heart J. 2015 Jan;23(1):35-41. doi: 10.1007/s12471-014-0619-8
  29. Schäfer U, Schirmer J, Niklas S, Harmel E, Deuschl F, Conradi L. First-in-human implantation of a novel transfemoral selfexpanding transcatheter heart valve to treat pure aortic regurgitation. EuroIntervention. 2017 Dec 20;13(11):1296-1299. doi: 10.4244/EIJ-D-17-00502
  30. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2023. THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study; 2022 Nov 18 [cited 2023 Apr 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02732704
  31. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2023. JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study; 2022 Nov 22 [cited 2023 Apr 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02732691
  32. Vahl T, Makkar R, Kodali S, et al. 30-DAY OUTCOMES OF TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT FOR AORTIC REGURGITATION WITH A NOVEL SELF-EXPANDING PROSTHESIS. J Am Coll Cardiol. 2021 May;77(18):919. doi: 10.1016/S0735-1097(21)02278-6
  33. Ochi A, Cheng K, Zhao B, Hardikar AA, Negishi K. Patient Risk Factors for Bioprosthetic Aortic Valve Degeneration: A Systematic Review and Meta-Analysis. Heart Lung Circ. 2020 May;29(5):668-678. doi: 10.1016/j.hlc.2019.09.013
  34. Arsalan M, Walther T. Durability of prostheses for transcatheter aortic valve implantation. Nat Rev Cardiol. 2016 Jun;13(6):360-7. doi: 10.1038/nrcardio.2016.43
  35. Hahn RT, Webb J, Pibarot P, et al. 5-Year Follow-Up From the PARTNER 2 Aortic Valve-in-Valve Registry for Degenerated Aortic Surgical Bioprostheses. JACC Cardiovasc Interv. 2022 Apr 11;15(7):698-708. doi: 10.1016/j.jcin.2022.02.014
  36. Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014 Jul;312(2):162-70. doi: 10.1001/jama.2014.7246
  37. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg. 2005 Mar;79(3):1072-80. doi: 10.1016/j.athoracsur.2004.06.033
  38. Bavaria JE, Griffith B, Heimansohn DA, et al. Five-year Outcomes of the COMMENCE Trial Investigating Aortic Valve Replacement with RESILIA Tissue. Ann Thorac Surg. 2022 Jan 20;S0003-4975(22)00063-7. doi: 10.1016/j.athoracsur.2021.12.058
  39. Lim KH, Candra J, Yeo JH, Duran CMG. Flat or curved pericardial aortic valve cusps: a finite element study. J Heart Valve Dis. 2004 Sep;13(5):792-7. PMID: 15473482
  40. Brizard CP, Brink J, Horton SB, Edwards GA, Galati JC, Neethling WML. New engineering treatment of bovine pericardium confers outstanding resistance to calcification in mitral and pulmonary implantations in a juvenile sheep model. J Thorac Cardiovasc Surg. 2014 Dec;148(6):3194-201. doi: 10.1016/j.jtcvs.2014.08.002
  41. Neethling W, Rea A, Forster G, Bhirangi K. Performance of the ADAPT-Treated CardioCel® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes. Front Pediatr. 2020 Apr 24;8:198. doi: 10.3389/fped.2020.00198
  42. Meduri C, Bapat V, Kodali S, et al. TCT-471 First-in-Human Study Results With the Novel Anteris DurAVRTM Three-Dimensional Single-Piece TAVR Device. J Am Coll Cardiol. 2022 Sep;80(12):B190. doi: 10.1016/j.jacc.2022.08.556
  43. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2023. Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study (DurAVR™ EFS); 2023 Mar 10 [cited 2023 Apr 20]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT05712161
  44. Bezuidenhout D, Williams DF, Zilla P. Polymeric heart valves for surgical implantation, catheter-based technologies and heart assist devices. Biomaterials. 2015 Jan;36:6-25. doi: 10.1016/j.biomaterials.2014.09.013
  45. Kereiakes DJ, Answini GA, Yakubov SJ, et al. Preliminary Evaluation of a Novel Polymeric Valve Following Surgical Implantation for Symptomatic Aortic Valve Disease. JACC Cardiovasc Interv. 2021 Dec 27;14(24):2754-2756. doi: 10.1016/j.jcin.2021.08.071
  46. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2023. Early Feasibility Study for the Foldax Tria Aortic Heart Valve; 2022 Feb 25 [cited 2023 Apr 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03851068
  47. Isrctn.com [Internet]. London, UK: Springer Nature; c2023. The role of cerebral embolic protection in preventing strokes and improving other health outcomes in patients receiving a replacement heart valve; 2022 Nov 11 [cited 2023 Apr 20]. Available from: https://www.isrctn.com/ISRCTN16665769
DOI: https://doi.org/10.14797/mdcvj.1230 | Journal eISSN: 1947-6108
Language: English
Page range: 4 - 14
Submitted on: Mar 14, 2023
Accepted on: Mar 15, 2023
Published on: May 16, 2023
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2023 Syed Zaid, Marvin D. Atkins, Neal S. Kleiman, Michael J. Reardon, Gilbert H. L. Tang, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.